SCHEMBL5481836

SCHEMBL5481836

NN(CC1c2ccccc2-c2ccccc21)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.47
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
KMT2A Q03164 3/20 0.40
TSHR P16473 2/20 0.40
CYP1A2 P05177 1/20 0.40
FABP7 O15540 2/20 0.39
FABP5 Q01469 2/20 0.39
MAPT P10636 1/20 0.39
HSD17B10 Q99714 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29129339 0.79 KMT2A (0.45) HTR2AKMT2ATSHRCYP1A2FABP7
SCHEMBL17454912 0.77 HTR2A (0.46) HTR2ACA1CA2KMT2ATSHR
Hydrochloric Acid SCHEMBL31031926 0.76 HTR2A (0.44) HTR2ACA1CA2KMT2ATSHR
SCHEMBL3740798 0.75 HTR2A (0.39) HTR2ACA1CA2KMT2ATSHR
SCHEMBL3660751 0.75 KMT2A (0.43) HTR2AKMT2ATSHRCYP1A2FABP7
SCHEMBL25373589 0.75 ALDH1A1 (0.41) HTR2ACA1CA2KMT2ATSHR
SCHEMBL16242267 0.75 KMT2A (0.40) HTR2ACA1CA2KMT2ATSHR
SCHEMBL3234063 0.74 HTR2A (0.40) HTR2ACA1CA2KMT2ATSHR
SCHEMBL1639593 0.73 HTR2A (0.38) HTR2ACA1CA2KMT2ATSHR
SCHEMBL452953 0.73 TSHR (0.40) HTR2AKMT2ATSHRCYP1A2FABP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056106-B1 SUGAR CHAIN-CAPTURING SUBSTANCE AND USE THEREOF SUMITOMO BAKELITE CO (JP) 2017-10-11 EP claimed
EP-4406606-A2 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G Bayer Pharma Aktiengesellschaft (DE) 2024-07-31 EP disclosed
EP-3086814-B1 DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) Bayer Pharma AG (DE) 2020-06-24 EP disclosed
EP-3310440-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS Bayer Pharma Aktiengesellschaft (DE) 2018-04-25 EP disclosed
WO-2016207089-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-29 WO disclosed
EP-3086814-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) Bayer Pharma Aktiengesellschaft (DE) 2016-11-02 EP disclosed
WO-2015096982-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-07-02 WO disclosed
US-20070208021-A1 Phenoxyacetic Acid Derivatives and Drug Comprising The Same DAIICHI PHARMACEUTICAL CO., LTD. 2007-09-06 US disclosed
CN-1938287-A Phenoxyacetic acid derivative and medicine containing the same DAIICHI SEIYAKU CO (JP) 2007-03-28 CN disclosed
EP-1731513-A1 PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208021-A1 Phenoxyacetic Acid Derivatives and Drug Comprising The Same PPARA, PPARG, PPARD HTR2A 457/4885CA1 3953/4885CA2 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.